According to Forbes, more than 3,000 new Risperdal lawsuits have been filed against Johnson & Johnson subsidiary Janssen Pharmaceuticals, Inc., in the first three months of 2017, bringing the total of Risperdal filings to more than 5,500.
The filings come on the heels of a $70 million jury award to a Tennessee plaintiff in 2016 for failure to warn that the antipsychotic drug Risperdal can cause gynecomastia, a condition that triggers breast development in boys and young men. According to the article, Johnson & Johnson cancelled the tolling agreement on thousands of cases, which paused the statute of limitations deadline for suits to be filed in multidistrict litigation (MDL) in Philadelphia.
First approved in 1993 for use in adults with schizophrenia, Risperdal has been frequently prescribed for children with ADHD and aggressive behaviors, even though the FDA did not approve the drug for pediatric use until 2006. A majority of the plaintiffs in pending litigation took Risperdal before it was approved for use in children. J&J paid $2.2 billion in fines in 2013 after the U.S. Department of Justice accused the company of marketing the drug illegally.
To date, eight Risperdal cases have been tried in the Philadelphia MDL. Four of the cases were dismissed and four resulted in verdicts for the plaintiffs. Since the tolling agreement has been cancelled, time is running out for other similar Risperdal claims to be filed.
Anyone with a prospective claim should consult with a personal injury attorney to ensure the court does not bar their claims. Approximately 80 percent of the Risperdal suits filed to date in the Philadelphia MDL are from out of state.
If you or a loved one has suffered an injury or injustice, the experienced personal injury legal team at Roberts & Roberts is here to help with compassionate, aggressive representation. Please call 800-248-6000 or contact us for a free consultation.